ATC Group: L01EM04 Duvelisib

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01EM04 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01E Protein kinase inhibitors
4 L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors
5 L01EM04

Active ingredients in L01EM04

Active Ingredient Description
Duvelisib

Duvelisib is a dual inhibitor of phosphatidylinositol 3-kinase p110δ (PI3K-δ) and PI3K-γ. PI3K-δ inhibition directly reduces proliferation and survival of malignant B-cell lines and primary CLL tumour cells, while PI3K-γ inhibition reduces the activity of CD4+ T cells and macrophages in the tumor microenvironment to support the malignant B cells.

Related product monographs

Title Information Source Document Type  
COPIKTRA Capsule FDA, National Drug Code (US) MPI, US: SPL/PLR
COPIKTRA Hard capsule European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Austria (AT)

Croatia (HR)

Estonia (EE)

France (FR)

Ireland (IE)

Italy (IT)

Lithuania (LT)

Poland (PL)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.